These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 33244378)

  • 21. In silico approach: docking study of oxindole derivatives against the main protease of COVID-19 and its comparison with existing therapeutic agents.
    Shah VR; Bhaliya JD; Patel GM
    J Basic Clin Physiol Pharmacol; 2021 Feb; 32(3):197-214. PubMed ID: 33594850
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular Docking of Azithromycin, Ritonavir, Lopinavir, Oseltamivir, Ivermectin and Heparin Interacting with Coronavirus Disease 2019 Main and Severe Acute Respiratory Syndrome Coronavirus-2 3C-Like Proteases.
    Arouche TDS; Martins AY; Ramalho TC; Júnior RNC; Costa FLP; Filho TSA; Neto AMJC
    J Nanosci Nanotechnol; 2021 Apr; 21(4):2075-2089. PubMed ID: 33500022
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SARS-CoV-2 proteases Mpro and PLpro: Design of inhibitors with predicted high potency and low mammalian toxicity using artificial neural networks, ligand-protein docking, molecular dynamics simulations, and ADMET calculations.
    Tumskiy RS; Tumskaia AV; Klochkova IN; Richardson RJ
    Comput Biol Med; 2023 Feb; 153():106449. PubMed ID: 36586228
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of apigenin-based biflavonoid derivatives as potential therapeutic agents against viral protease (3CLpro) of SARS-CoV-2 via molecular docking, molecular dynamics and quantum mechanics studies.
    Abdizadeh R; Hadizadeh F; Abdizadeh T
    J Biomol Struct Dyn; 2023; 41(13):5915-5945. PubMed ID: 35848354
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structure-based computational screening of 470 natural quercetin derivatives for identification of SARS-CoV-2 M
    Kakhar Umar A; Zothantluanga JH; Luckanagul JA; Limpikirati P; Sriwidodo S
    PeerJ; 2023; 11():e14915. PubMed ID: 36935912
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Peptide-like and small-molecule inhibitors against Covid-19.
    Pant S; Singh M; Ravichandiran V; Murty USN; Srivastava HK
    J Biomol Struct Dyn; 2021 May; 39(8):2904-2913. PubMed ID: 32306822
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current Insights and Molecular Docking Studies of the Drugs under Clinical Trial as RdRp Inhibitors in COVID-19 Treatment.
    Pauly I; Kumar Singh A; Kumar A; Singh Y; Thareja S; Kamal MA; Verma A; Kumar P
    Curr Pharm Des; 2022; 28(46):3677-3705. PubMed ID: 36345244
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug repurposing studies targeting SARS-CoV-2: an ensemble docking approach on drug target 3C-like protease (3CL
    Koulgi S; Jani V; Uppuladinne M; Sonavane U; Nath AK; Darbari H; Joshi R
    J Biomol Struct Dyn; 2021 Sep; 39(15):5735-5755. PubMed ID: 32679006
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A multi-stage virtual screening of FDA-approved drugs reveals potential inhibitors of SARS-CoV-2 main protease.
    Mandour YM; Zlotos DP; Alaraby Salem M
    J Biomol Struct Dyn; 2022 Mar; 40(5):2327-2338. PubMed ID: 33094680
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exploration of Novel Lichen Compounds as Inhibitors of SARS-CoV-2 Mpro: Ligand-Based Design, Molecular Dynamics, and ADMET Analyses.
    Gupta A; Sahu N; Singh AP; Singh VK; Singh SC; Upadhye VJ; Mathew AT; Kumar R; Sinha RP
    Appl Biochem Biotechnol; 2022 Dec; 194(12):6386-6406. PubMed ID: 35921031
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease.
    Kandeel M; Al-Nazawi M
    Life Sci; 2020 Jun; 251():117627. PubMed ID: 32251634
    [TBL] [Abstract][Full Text] [Related]  

  • 32. COVID-19: Rational discovery of the therapeutic potential of Melatonin as a SARS-CoV-2 main Protease Inhibitor.
    Feitosa EL; Júnior FTDSS; Nery Neto JAO; Matos LFL; Moura MHS; Rosales TO; De Freitas GBL
    Int J Med Sci; 2020; 17(14):2133-2146. PubMed ID: 32922174
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In silico discovery of novel inhibitors from Northern African natural products database against main protease (Mpro) of SARS-CoV-2.
    Byadi S; Oblak D; Kassmi Y; Sadik K; Hachim ME; Podlipnik Č; Aboulmouhajir A
    J Biomol Struct Dyn; 2023 Apr; 41(7):2900-2910. PubMed ID: 35168469
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Allergen fragrance molecules: a potential relief for COVID-19.
    Aydın AD; Altınel F; Erdoğmuş H; Son ÇD
    BMC Complement Med Ther; 2021 Jan; 21(1):41. PubMed ID: 33478471
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of the dual effects of antiviral drugs on SARS-CoV-2 receptors and the ACE2 receptor using structure-based virtual screening and molecular dynamics simulation.
    Jahantigh HR; Ahmadi N; Shahbazi B; Lovreglio P; Habibi M; Stufano A; Gouklani H; Ahmadi K
    J Biomol Struct Dyn; 2023; 41(13):6051-6073. PubMed ID: 35876061
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of potential Mpro inhibitors for the treatment of COVID-19 by using systematic virtual screening approach.
    Kanhed AM; Patel DV; Teli DM; Patel NR; Chhabria MT; Yadav MR
    Mol Divers; 2021 Feb; 25(1):383-401. PubMed ID: 32737681
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
    Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M
    Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Virtual screening of approved drugs as potential SARS-CoV-2 main protease inhibitors.
    Jiménez-Alberto A; Ribas-Aparicio RM; Aparicio-Ozores G; Castelán-Vega JA
    Comput Biol Chem; 2020 Oct; 88():107325. PubMed ID: 32623357
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Screening of FDA Approved Drugs Against SARS-CoV-2 Main Protease: Coronavirus Disease.
    Balakrishnan V; Lakshminarayanan K
    Int J Pept Res Ther; 2021; 27(1):651-658. PubMed ID: 33013255
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular docking, binding mode analysis, molecular dynamics, and prediction of ADMET/toxicity properties of selective potential antiviral agents against SARS-CoV-2 main protease: an effort toward drug repurposing to combat COVID-19.
    Rai H; Barik A; Singh YP; Suresh A; Singh L; Singh G; Nayak UY; Dubey VK; Modi G
    Mol Divers; 2021 Aug; 25(3):1905-1927. PubMed ID: 33582935
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.